MarketCapExport financials
Evofem Biosciences (EVFM)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Evofem Biosciences Income Statement 2025-2011 | EVFM
Brief overview of financial performance at Evofem Biosciences
This overview is based on financial performance over the past five years. Evofem Biosciences reported revenue of 446 thousand dollars in 2020 and 20.2 million dollars by 2025. The five-year change reached +4425.3%, while CAGR stood at 114.4%. Sales grew at a rate typical of a strong expansion phase.
At the gross-profit level, the result moved from −$22 thousand to $15.6 million, a change of +70854.5%. Cost of revenue developed more favorably than sales, supporting gross profitability. Gross profit as a share of revenue changed from −4.9% to 77.1%. The margin shift points to a more favorable sales-and-cost structure.
The operating result measured by EBITDA moved from −$103 million to $3.4 million, or +103.3%. Operating performance weakened relative to revenue. EBITDA margin was −23166.4% at the start and 16.8% at the end. The business generated more EBITDA from each unit of revenue.
Net income moved from −$142 million at the start to $391 thousand at the end. The business moved out of a loss and ended the period with a profit.
Summary assessment
The indicators form a favorable picture of business development. The financial profile benefits from net-income growth, a larger revenue base and higher operating efficiency. Further direction will depend on top-line growth, operating profitability, and net income.
Annual Income Statement Evofem Biosciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
- | - | 3.86 M | 373 K | 59.2 M | 177 M | 207 M | 72.3 M | 20.9 M | 18.4 M | 14.5 M | 13.5 M | - | - | - |
Shares |
124 M | 80 M | 4.83 M | 466 K | 8.73 M | 67.2 M | 40.2 M | 21.9 M | 2.31 M | 2.3 M | 2.28 M | 336 K | - | - | - |
Historical Prices |
- | - | 0.8 | 0.8 | 6.78 | 39.5 | 74.2 | 51 | 131 | 137 | 95.4 | 600 | - | - | - |
Net Income |
391 K | -8.86 M | 53 M | -76.7 M | -205 M | -142 M | -80 M | -126 M | -9.99 M | -13 M | -43.2 M | -10.8 M | -15 M | -7.83 M | - |
Revenue |
20.2 M | 19.4 M | 18.2 M | 16.8 M | 8.24 M | 446 K | - | - | - | - | - | - | - | 100 K | - |
Cost of Revenue |
4.62 M | 3.83 M | 6.51 M | 4.42 M | 4.06 M | 468 K | - | - | - | - | - | - | - | - | - |
Gross Profit |
- | - | - | - | - | -22 K | - | - | - | - | - | - | - | - | - |
Operating Income |
3.37 M | -7.68 M | -17.8 M | -84.1 M | -167 M | -104 M | -52.7 M | -77.6 M | -35.7 M | -34.6 M | -42 M | -9.59 M | -14.4 M | - | - |
Interest Expense |
2.37 M | 2.24 M | 2.27 M | 2.18 M | 2.66 M | 2.06 M | - | -145 K | -46 K | 38 K | - | - | -47.3 K | - | - |
EBITDA |
3.39 M | -7.65 M | -17.4 M | -83.1 M | -166 M | -103 M | -52.5 M | -77.4 M | -10 M | -12 M | -42 M | -9.57 M | -14.4 M | -5.62 M | - |
Operating Expenses |
- | - | - | - | - | 104 M | 52.7 M | 77.6 M | 10 M | 12 M | 42 M | - | - | - | - |
General and Administrative Expenses |
7.39 M | 11.6 M | 15 M | 27.6 M | 24.7 M | 30.1 M | 30.5 M | 34.2 M | 6.1 M | 5.46 M | 7.64 M | 4.42 M | 2.97 M | 2.59 M | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Income Statement Evofem Biosciences
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
133 M | 120 M | 116 M | 113 M | 113 M | 96.5 M | 66.8 M | 31.2 M | 20 M | 4.24 M | 1.58 M | 1.27 M | 985 K | 659 K | 217 K | 88.7 K | 10.8 M | 10.3 M | 8.34 M | 5.46 M | 81.4 M | 81.2 M | 57.7 M | 48.2 M | 48.1 M | 46.2 M | 36.7 M | 26.9 M | 25.9 M | 25.8 M | 20.9 M | 15 M | 2.08 M | 1.96 M | 1.96 M | 1.96 M | 81.1 M | 13.8 M | 13.8 M | 13.8 M | 13.8 M | 13.7 M | 13.7 M | 13.7 M | 13.7 M | 552 K | 552 K | 534 K | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income |
-5.46 M | -1.57 M | -1.78 M | 956 K | - | -2.36 M | 1.35 M | -4.81 M | - | 66 M | -8.56 M | -2.35 M | - | 89.5 M | -126 M | -31.9 M | - | -74.1 M | -33.4 M | -46.2 M | - | -29.9 M | -52.7 M | -19.1 M | -12.7 M | -13.8 M | -35.4 M | -18.1 M | -15 M | -18.4 M | -23.2 M | -69.1 M | -19.5 M | -74 M | -6.51 M | -5.27 M | -14.2 M | -33.5 M | -6.86 M | -13.2 M | - | -17.3 M | -9.48 M | -6.9 M | - | -4.04 M | -2.28 M | -1.6 M | - | - | - | - | - | - | - | - | - | - | - | - |
Revenue |
899 K | 4.95 M | 4.82 M | 845 K | - | 4.5 M | 4.16 M | 3.6 M | - | 5.11 M | 2.46 M | 5.81 M | - | 6.37 M | 6.03 M | 4.25 M | - | 1.71 M | 1.86 M | 1.1 M | - | 278 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
410 K | 905 K | 755 K | 365 K | - | 869 K | 769 K | 684 K | - | 1.89 M | 2.29 M | 1.38 M | - | 1.68 M | 1.28 M | 1.07 M | - | 955 K | 839 K | 506 K | - | 317 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-4.57 M | 951 K | -1.25 M | 327 K | - | -2.44 M | -1.39 M | -2.84 M | - | -3.55 M | -7.34 M | -3.58 M | - | -18.7 M | -24.4 M | -28.9 M | - | -43.4 M | -41.1 M | -44.9 M | - | -26.2 M | -22.4 M | -19.2 M | - | -14.3 M | -11.9 M | -13.6 M | - | -18.4 M | -23.2 M | -21 M | - | -9.07 M | -6.36 M | -4.91 M | - | -1.87 M | -2.52 M | -5.78 M | - | -17 M | -9.2 M | -6.64 M | - | -1.87 M | -1.98 M | -2.48 M | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expense |
614 K | - | - | 577 K | - | - | - | 564 K | - | -596 K | -1.13 M | 565 K | - | -436 K | -415 K | 523 K | - | 2.15 M | 1.65 M | 1.15 M | - | 992 K | 344 K | - | - | - | - | -14 K | - | -33 K | -32 K | -50 K | - | -42 K | 64 K | -34 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
-4.56 M | 1.03 M | -1.14 M | 333 K | - | -2.14 M | - | -2.83 M | - | -3.05 M | -7.14 M | -3.33 M | - | -18 M | -23.9 M | -28.7 M | - | -42.6 M | -40.7 M | -44.7 M | - | -26 M | -22.2 M | -19.2 M | - | -14.1 M | -11.8 M | -13.6 M | - | -18.2 M | -23.1 M | -20.9 M | - | -8.89 M | -6.24 M | -4.86 M | - | -1.82 M | -2.48 M | -5.76 M | - | -16.9 M | -9.18 M | -6.63 M | - | -1.85 M | -1.97 M | -2.48 M | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Expenses |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 45.1 M | 43 M | 46 M | - | 26.4 M | 22.4 M | 19.2 M | 12.9 M | 14.3 M | 11.9 M | 13.6 M | 15 M | 18.4 M | 23.2 M | 21 M | 15.3 M | 9.07 M | 6.36 M | 4.91 M | 7.32 M | 7.04 M | 7 M | 13.3 M | - | 17 M | 9.2 M | 6.64 M | - | 1.87 M | 1.98 M | 2.48 M | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
2.37 M | 2.09 M | 1.84 M | 2.36 M | - | 3.05 M | 2.27 M | 2.82 M | - | 3.18 M | 4.9 M | 3.62 M | - | 6.26 M | 9.13 M | 9.02 M | - | 4.96 M | 6.42 M | 7.68 M | - | 7.2 M | 9.74 M | 7.14 M | - | 4.84 M | 5.38 M | 4.62 M | - | 8.58 M | 11.4 M | 9.03 M | - | 2.81 M | 2.28 M | 2.93 M | - | 905 K | 1.09 M | 2.52 M | - | 1.77 M | 1.73 M | 1.94 M | - | 923 K | 1.05 M | 1.1 M | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
The income statement is one of the three key financial reports of a company Evofem Biosciences (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Reports on the profits and losses of other stocks in the Biotechnology industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Innate Pharma S.A.
IPHA
|
$ 1.54 | 1.98 % | $ 138 M |  France |
 |
Seneca Biopharma, Inc.
SNCA
|
- | -1.19 % | $ 28.7 M |  USA |
 |
BioMarin Pharmaceutical
BMRN
|
$ 57.1 | -0.14 % | $ 11 B | USA |
 |
Matinas BioPharma Holdings
MTNB
|
$ 1.19 | -4.03 % | $ 6.51 M | USA |
 |
Enanta Pharmaceuticals
ENTA
|
$ 11.24 | -2.01 % | $ 240 K | USA |
 |
SIGA Technologies
SIGA
|
$ 3.14 | -3.83 % | $ 225 M | USA |
 |
Milestone Pharmaceuticals
MIST
|
$ 0.68 | -7.49 % | $ 72.2 M |  Canada |
 |
Kiniksa Pharmaceuticals, Ltd.
KNSA
|
$ 94.9 | -3.91 % | $ 7.04 B | USA |
 |
Lipocine
LPCN
|
$ 1.59 | -7.85 % | $ 8.66 M | USA |
 |
PTC Therapeutics
PTCT
|
$ 64.12 | -1.4 % | $ 5.1 B | USA |
 |
Seres Therapeutics
MCRB
|
$ 1.55 | -8.75 % | $ 13.7 M | USA |
 |
Madrigal Pharmaceuticals
MDGL
|
$ 432.48 | -0.07 % | $ 9.7 B | USA |
 |
CEL-SCI Corporation
CVM
|
$ 1.41 | 4.07 % | $ 11.3 M | USA |
 |
Inventiva S.A.
IVA
|
$ 3.95 | 2.73 % | $ 236 M | France |
 |
MeiraGTx Holdings plc
MGTX
|
$ 9.62 | 1.37 % | $ 774 M | USA |
 |
Processa Pharmaceuticals
PCSA
|
$ 1.86 | -4.62 % | $ 2.44 M | USA |
 |
Eton Pharmaceuticals
ETON
|
$ 67.5 | 4.9 % | $ 1.82 B | USA |
 |
IDEAYA Biosciences
IDYA
|
$ 31.72 | -0.97 % | $ 2.81 B | USA |
 |
Protalix BioTherapeutics
PLX
|
$ 2.86 | 11.28 % | $ 225 M |  Israel |
 |
Lantern Pharma
LTRN
|
$ 0.47 | -22.86 % | $ 5.12 M | USA |
 |
Foghorn Therapeutics
FHTX
|
$ 1.89 | -7.35 % | $ 119 M | USA |
 |
Ocugen
OCGN
|
$ 0.95 | -2.45 % | $ 297 M | USA |
 |
Oncolytics Biotech
ONCY
|
$ 0.38 | -5.64 % | $ 36.4 M | Canada |
 |
Minerva Neurosciences
NERV
|
$ 2.47 | -6.08 % | $ 20.9 M | USA |
 |
Kamada Ltd.
KMDA
|
$ 8.09 | 4.93 % | $ 466 M | Israel |
 |
Neurocrine Biosciences
NBIX
|
$ 169.08 | 0.13 % | $ 16.8 B | USA |
 |
Nanobiotix S.A.
NBTX
|
$ 32.8 | 2.4 % | $ 1.57 T | France |
 |
Mereo BioPharma Group plc
MREO
|
$ 0.3 | 1.66 % | $ 239 M |  Britain |
 |
Maravai LifeSciences Holdings
MRVI
|
$ 7.86 | -2.31 % | $ 1.13 B | USA |
 |
Lexicon Pharmaceuticals
LXRX
|
$ 1.84 | 0.82 % | $ 668 M | USA |
 |
Moleculin Biotech
MBRX
|
$ 8.01 | -7.51 % | $ 9.49 M | USA |
 |
Nurix Therapeutics
NRIX
|
$ 15.89 | -1.58 % | $ 1.38 B | USA |
 |
Nkarta
NKTX
|
$ 1.36 | -14.78 % | $ 101 M | USA |
 |
MacroGenics
MGNX
|
$ 2.42 | 3.42 % | $ 153 M | USA |
 |
Protagonist Therapeutics
PTGX
|
$ 136.18 | 0.2 % | $ 8.66 B | USA |
|
Nuvation Bio
NUVB
|
$ 4.22 | -3.1 % | $ 1.44 B | USA |
 |
Novo Nordisk A/S
NVO
|
$ 40.6 | -1.88 % | $ 180 B |  Danmark |
 |
Marker Therapeutics
MRKR
|
$ 0.95 | -3.87 % | $ 14.5 M | USA |
 |
NextCure
NXTC
|
$ 5.97 | -4.78 % | $ 17 M | USA |
 |
Rocket Pharmaceuticals
RCKT
|
$ 2.46 | -2.96 % | $ 273 M | USA |
 |
PMV Pharmaceuticals
PMVP
|
$ 1.22 | -2.8 % | $ 64.1 M | USA |
 |
Olema Pharmaceuticals
OLMA
|
$ 7.29 | -1.02 % | $ 634 M | USA |
 |
Kymera Therapeutics
KYMR
|
$ 136.45 | -1.74 % | $ 11.5 B | USA |
 |
Oragenics
OGEN
|
$ 0.35 | -1.47 % | $ 755 K | USA |
 |
Ovid Therapeutics
OVID
|
$ 2.8 | -1.75 % | $ 365 M | USA |
 |
Passage Bio
PASG
|
$ 3.81 | 11.08 % | $ 12.2 M | USA |
 |
Vaxcyte
PCVX
|
$ 66.44 | -1.61 % | $ 9.04 B | USA |
 |
Relay Therapeutics
RLAY
|
$ 19.81 | -2.87 % | $ 3.4 B | USA |
 |
Precigen
PGEN
|
$ 4.51 | -4.76 % | $ 1.41 B | USA |
 |
Avidity Biosciences
RNA
|
$ 8.23 | -1.79 % | $ 1.13 B | USA |